# LEO 90100 in the Treatment of Psoriasis Vulgaris

> **NCT01536938** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 303 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 90100
- **DRUG:** Calcipotriol
- **DRUG:** Betamethasone

## Key facts

- **NCT ID:** NCT01536938
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-11
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536938, "LEO 90100 in the Treatment of Psoriasis Vulgaris". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT01536938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*